FDA Panel To Consider Potential Tumor Risk With Fibrocell Science's Wrinkle Therapy
This article was originally published in The Pink Sheet Daily
The Cellular, Tissue and Gene Therapies Advisory Committee meets Oct. 9 to discuss the first cellular product proposed to treat nasolabial facial wrinkles.
You may also be interested in...
Advisory committee votes that Laviv (azfibrocel-T) is effective in improving nasolabial fold wrinkles, but that safety data are too limited to be relied upon - especially considering the inevitably widespread off-label use.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.